510(k) · Cleared
ClearedIS-Vzu Igg Test System
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Diamedix Corp. · LFY Enzyme Linked Immunoabsorbent Assay, Varicella-Zoster
Cleared on Sep 28, 1998 after a 123-day review. The FDA summary names its predicate without a number. 3 later devices descend from it.
- Decided
- Sep 28, 1998
- Review
- 123 days
- Class
- Class II
- Product code
- LFY
- Recalls
- None
- Predicates
- 0
3 later devices descend from it, 1 citing it directly.
- This deviceK981867 IS-Vzu Igg Test SystemDiamedix Corp. · 1998
- Descendant · cites it directly · 2 of its ownK061820 Diasorin Liaison VZV IggDiaSorin, Inc. · 2007
- Descendant · 2 generations on · 1 of its ownK150375 LIAISON VZV IgG, LIAISON Control VZV IgGDiaSorin, Inc. · 2015
- Descendant · 3 generations on · 0 of its ownK231214 LIAISON VZV IgG HT, LIAISON Control VZV IgG HTDiaSorin, Inc. · 2023
Most influential descendants
Showing 3 of 3 · See allView FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| 0 (this device) | K981867 | IS-Vzu Igg Test System | Diamedix Corp. | 1998 | — |
| +1 | K061820 | Diasorin Liaison VZV Igg | DiaSorin, Inc. | 2007 | — |
| +2 | K150375 | LIAISON VZV IgG, LIAISON Control VZV IgG | DiaSorin, Inc. | 2015 | — |
| +3 | K231214 | LIAISON VZV IgG HT, LIAISON Control VZV IgG HT | DiaSorin, Inc. | 2023 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2007 | 1 | 0 |
| 2015 | 1 | 0 |
| 2023 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in LFY? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new LFY device
- #1 K231214 LIAISON VZV IgG HT, LIAISON Control VZV IgG HTscore 6.8 · 3 generations · no Class I recall
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | — | Diamedix VZVMicroassay Named without a submission number |
What descends from it? (3)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K061820 | Diasorin Liaison VZV Igg | 2007 | 2 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- Of its descendants, K061820 (DiaSorin, Inc., 2007) has gone furthest, with 2 descendants of its own.
How does its category compare?
All LFY devicesLFY Enzyme Linked Immunoabsorbent Assay, Varicella-Zoster: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · LFY
1in 2023
2026 to Oct 25, outlined.
Median 510(k) review, days · LFY
Too few LFY 510(k)s in any year since 2007 to give a median.
Recalls per year · LFY
1in 2022
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · LFY
2in 2024
MAUDE reports naming product code LFY, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 2 | — | 0 | 0 |
| 2008 | 0 | — | 1 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 0 | — | 0 | 0 |
| 2015 | 1 | — | 0 | 20 |
| 2016 | 0 | — | 0 | 2 |
| 2017 | 0 | — | 0 | 0 |
| 2018 | 0 | — | 0 | 2 |
| 2019 | 0 | — | 0 | 2 |
| 2020 | 0 | — | 0 | 0 |
| 2021 | 0 | — | 0 | 0 |
| 2022 | 0 | — | 1 | 2 |
| 2023 | 1 | — | 0 | 1 |
| 2024 | 0 | — | 0 | 2 |
| 2025 | 0 | — | 0 | 0 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
For the qualitative and semi-quantitative detection of IgG antibodies to Varicella-Zoster Virus (VZV) in human serum by indirect immunoassay to determine a prior exposure to VZV and, when evaluating paired sera, to aid in the determination of acute or convalescent stage of VZV infection. These reagents can be used either manually or in conjunction with the MAGO® Plus Automated EIA Processor.
Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.
https://510kreport.com/device/K981867 · printed Nov 6, 2026
Cite this page
510(k) Report. “K981867: IS-Vzu Igg Test System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K981867
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026